# Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

> **NCT02959138** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 36 (actual)

## Conditions studied

- Inflammatory Disease

## Interventions

- **DRUG:** Lanraplenib.

## Key facts

- **NCT ID:** NCT02959138
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959138, "Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02959138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*